A CRISPR kidney that is part pig, part person is just another step toward editing our children’s genes. Call it sci-fi ...

The obesity rate has more than doubled in the last 30 years, affecting more than one billion people worldwide.

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Salk Institute scientists are looking for a new treatment strategy in microproteins, an understudied class of molecules found ...

Researchers developed a method to dissect immune-regulatory programs via integrative time-series analysis and high-content CRISPR screening.

Mars, maker of M&M's and Skittles, is turning to CRISPR gene editing to develop more resilient cacao plants, with the aim of ...

The obesity rate has more than doubled in the last 30 years, affecting more than one billion people worldwide. This prevalent ...

CRISPR Therapeutics, trading under, operates within the biotechnology sector, a key area of interest within the broader ...

CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 ...

The FDA's approval of the first CRISPR-Cas9–based gene therapy marked a major milestone in biomedicine, validating genome ...

CRISPR Therapeutics (CRSP) stock falls as company's Q2 results miss consensus amid focus on its Cagevy gene therapy developed with Vertex Pharma (VRTX). Read more here.